D.E. Shaw & Co’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

D.E. Shaw & Co’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-83,400	Closed	-$1.81M	–	3947
2015 Q4	$1.81M	Hold	83,400	–	–	﹤0.01%	2209
2015 Q3	$1.65M	Sell	83,400 -40,000	-32%	-$1.26M	﹤0.01%	2229
2015 Q2	$4.29M	Buy	+123,400	New	+$3.77M	0.01%	1586
2015 Q1	–	Sell	-10,000	Closed	-$129K	–	4164
2014 Q4	$129K	Hold	10,000	–	–	﹤0.01%	3878
2014 Q3	$123K	Sell	10,000 -80,000	-89%	-$930K	﹤0.01%	3962
2014 Q2	$1.42M	Hold	90,000	–	–	﹤0.01%	2609
2014 Q1	$1.36M	Buy	+90,000	New	+$1.02M	﹤0.01%	2767

Other funds holding HZNP

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

VWA

Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return

FSWA

Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return

BCMLT

Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

D.E. Shaw & Co's HZNP Position: Q4 2023 in Review

D.E. Shaw & Co sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 4,718,246 shares — an estimated $546M sold.

D.E. Shaw & Co first reported a position in HZNP in Q3 2013 and held it in 40 quarters. The position peaked at $546M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

D.E. Shaw & Co reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
D.E. Shaw & Co sold 4,718,246 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $546M.
D.E. Shaw & Co first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2013 and held it in 40 quarters.
D.E. Shaw & Co's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $546M in Q3 2023.
6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on D.E. Shaw & Co's 13F filing for Q4 2023, filed 14 Feb 2024.